Company Quick10K Filing
Celgene
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 727 $67,154
10-Q 2019-10-31 Quarter: 2019-09-30
10-Q 2019-07-30 Quarter: 2019-06-30
10-Q 2019-04-25 Quarter: 2019-03-31
10-K 2019-02-26 Annual: 2018-12-31
10-Q 2018-10-25 Quarter: 2018-09-30
10-Q 2018-07-26 Quarter: 2018-06-30
10-Q 2018-05-04 Quarter: 2018-03-31
10-K 2018-02-07 Annual: 2017-12-31
10-Q 2017-10-26 Quarter: 2017-09-30
10-Q 2017-07-27 Quarter: 2017-06-30
10-Q 2017-04-27 Quarter: 2017-03-31
10-K 2017-02-10 Annual: 2016-12-31
10-Q 2016-10-27 Quarter: 2016-09-30
10-Q 2016-07-28 Quarter: 2016-06-30
10-Q 2016-05-03 Quarter: 2016-03-31
10-K 2016-02-11 Annual: 2015-12-31
10-Q 2015-11-05 Quarter: 2015-09-30
10-Q 2015-07-28 Quarter: 2015-06-30
10-Q 2015-04-30 Quarter: 2015-03-31
10-K 2015-02-20 Annual: 2014-12-31
10-Q 2014-10-28 Quarter: 2014-09-30
10-Q 2014-07-29 Quarter: 2014-06-30
10-Q 2014-04-29 Quarter: 2014-03-31
10-K 2014-02-13 Annual: 2013-12-31
10-Q 2013-10-29 Quarter: 2013-09-30
10-Q 2013-07-30 Quarter: 2013-06-30
10-Q 2013-04-30 Quarter: 2013-03-31
10-K 2013-02-15 Annual: 2012-12-31
10-Q 2012-10-29 Quarter: 2012-09-30
10-Q 2012-08-01 Quarter: 2012-06-30
10-Q 2012-05-02 Quarter: 2012-03-31
10-K 2012-02-22 Annual: 2011-12-31
10-Q 2011-11-02 Quarter: 2011-09-30
10-Q 2011-08-03 Quarter: 2011-06-30
10-Q 2011-05-05 Quarter: 2011-03-31
10-K 2011-03-01 Annual: 2010-12-31
10-Q 2010-11-02 Quarter: 2010-09-30
10-Q 2010-08-04 Quarter: 2010-06-30
10-Q 2010-05-03 Quarter: 2010-03-31
10-K 2010-02-18 Annual: 2009-12-31
8-K 2019-11-21 M&A, Shareholder Rights, Exhibits
8-K 2019-11-15 Leave Agreement, M&A, Shareholder Rights, Control, Officers, Amend Bylaw, Other Events, Exhibits
8-K 2019-10-31 Earnings, Exhibits
8-K 2019-08-25 Enter Agreement, Exhibits
8-K 2019-07-30 Earnings, Exhibits
8-K 2019-04-25 Earnings, Exhibits
8-K 2019-04-12 Shareholder Vote, Other Events, Exhibits
8-K 2019-04-04 Other Events
8-K 2019-03-29 Other Events, Exhibits
8-K 2019-03-25 Other Events
8-K 2019-03-08 Regulation FD, Exhibits
8-K 2019-01-31 Earnings, Exhibits
8-K 2019-01-07 Earnings, Exhibits
8-K 2019-01-03 Other Events, Exhibits
8-K 2019-01-02 Enter Agreement, Officers, Exhibits
8-K 2018-11-01 Officers, Exhibits
8-K 2018-10-25 Earnings, Exhibits
8-K 2018-07-26 Earnings, Exhibits
8-K 2018-07-09 Other Events, Exhibits
8-K 2018-06-29 Other Events, Exhibits
8-K 2018-06-28 Other Events, Exhibits
8-K 2018-06-19 Other Events, Exhibits
8-K 2018-06-13 Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-05-31 Officers, Exhibits
8-K 2018-05-30 Regulation FD
8-K 2018-05-24 Other Events, Exhibits
8-K 2018-05-04 Earnings, Exhibits
8-K 2018-04-25 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-04-17 Officers, Exhibits
8-K 2018-04-02 Officers, Other Events, Exhibits
8-K 2018-03-06 M&A, Exhibits
8-K 2018-02-26 Other Events, Exhibits
8-K 2018-02-20 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-02-14 Other Events, Exhibits
8-K 2018-02-13 Officers, Exhibits
8-K 2018-02-08 Enter Agreement, Other Events, Exhibits
8-K 2018-02-08 Other Events, Exhibits
8-K 2018-02-06 Other Events, Exhibits
8-K 2018-02-02 Other Events, Exhibits
8-K 2018-01-26 Other Events, Exhibits
8-K 2018-01-25 Officers, Exhibits
8-K 2018-01-25 Earnings, Exhibits
8-K 2018-01-22 Regulation FD, Exhibits
8-K 2018-01-21 Enter Agreement, Exhibits
8-K 2018-01-08 Earnings, Exhibits
8-K 2018-01-07 Other Events, Exhibits

Celgene Financials

CELG Metrics, Comps, Filings

Annual | Quarterly

Business

Celgene Corporation, together with its subsidiaries (collectively "we," "our," "us," "Celgene" or the "Company"), is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Celgene Corporation was incorporated in the State of Delaware in 1986.

On January 2, 2019, we entered into a definitive merger agreement with Bristol-Myers Squibb Company (Bristol-Myers Squibb) under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion, based on the closing price of Bristol-Myers Squibb shares of $52.43 on January 2, 2019, subject to the terms and conditions set forth therein. The transaction is subject to approval by Bristol-Myers Squibb and Celgene shareholders and the satisfaction of customary closing conditions and regulatory approvals. Bristol-Myers Squibb and Celgene expect to complete the transaction in the third quarter of 2019. See Part I, Item 1A, "Risk Factors," Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," and Note 22 of the Notes to Consolidated Financial Statements included in this report for additional information regarding the transaction.

Our primary commercial stage products include REVLIMID®, POMALYST®/IMNOVID®, OTEZLA®, ABRAXANE®, and VIDAZA®.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Eli Lilly (LLY) 106,241 77% 11.8 20% 38,666 35,809 23,229 17,810 7,843 9,937 117,668
AbbVie (ABBV) 100,912 77% 18.0 7% 57,142 65,708 32,624 25,254 4,118 7,085 127,359
Beigene (BGNE) 98,573 88% -152.1 -31% 2,150 579 434 383 -664 -642 97,723
Bristol Myers Squibb (BMY) 73,829 53% 8.4 11% 55,163 39,012 23,857 12,640 6,226 8,365 69,858
Celgene (CELG) 67,154 96% 10.4 13% 39,183 29,132 16,354 15,736 5,271 7,702 79,730
GW Pharmaceuticals (GWPH) 64,239 88% -1,554.6 -6% 843 114 114 100 -50 -41 63,656
Allergan (AGN) 54,767 85% 80.8 -4% 123,846 38,273 15,678 13,341 -5,356 939 75,841
Zoetis (ZTS) 54,569 67% 25.9 13% 10,986 8,575 6,046 4,046 1,375 2,291 59,314
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 46,842 87% 16.9 33% 7,033 1,964 3,454 2,990 2,355 2,569 43,540
Regeneron Pharmaceuticals (REGN) 35,984 0% 15.2 16% 13,174 3,418 7,237 0 2,069 2,295 34,925
Alexion Pharmaceuticals (ALXN) 28,246 71% 15.7 9% 14,568 4,404 4,499 3,191 1,334 1,835 28,827
Biomarin Pharmaceutical (BMRN) 15,774 79% 680.7 -3% 4,393 1,432 1,533 1,213 -110 24 16,336
Elanco Animal Health (ELAN) 12,085 52% 30.6 2% 8,857 3,591 3,073 1,591 144 460 14,098
Mylan (MYL) 9,779 34% 8.3 0% 31,817 19,914 11,245 3,793 34 2,748 22,896
Teva (TEVA) 9,708 44% -13.7 -6% 59,424 44,173 17,720 7,741 -3,851 -2,437 33,498
Sarepta Therapeutics (SRPT) 9,465 0% -16.1 -33% 1,748 649 345 0 -570 -518 8,352
Ionis Pharmaceuticals (IONS) 9,097 57% 30.7 17% 2,878 1,421 799 459 495 287 8,825
Sage Therapeutics (SAGE) 8,814 51% -14.1 -47% 1,316 113 2 1 -613 -612 8,646
Bausch (BHC) 8,750 0% 25.1 -3% 32,354 29,666 8,425 0 -911 1,285 32,239

Balance Sheet ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash1,1021,3511,8592,0903,2344,1224,8806,1707,0134,234
Accounts Receivable4397069469611,0611,1671,4211,6211,9212,066
Inventory101260190259340393443498541458
PP&E2985105065781,0261,1668149301,0701,367
Assets5,38910,17710,00611,73413,37817,34027,05328,08630,14135,480
Accounts Payable3794122146156198241247305418
Long-Term Debt211,2942,8934,1966,98814,29914,57216,60019,300
Liabilities9954,1824,4936,0407,78810,81521,13421,48623,22029,319
Stockholders' Equity4,3955,9845,5135,6945,5906,5255,9196,5996,9216,161
Income Statement ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue2,5673,5084,7005,3866,3627,5649,16111,18512,97315,281
Cost of Revenue216307426299340386420438461587
Gross Profit2,3513,2024,2745,0866,0227,1788,74110,74712,51214,678
R&D7951,1281,6001,7242,2262,4313,6974,4705,9155,673
SG&A7549511,2261,3741,6842,0282,3052,6582,9413,250
Tax1991321022252922953613731,374786
Net Income7778801,3171,4561,4502,0001,6021,9992,9404,046
Cash Flow ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating9101,1821,8092,0192,2262,8062,4843,9765,2465,171
Cash Investing-856-2,107378-1,554-529-1,438-6,259-1,002-2,891-6,418
Cash Financing-621,177-1,655-249-554-4174,584-1,646-1,584-1,540